Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.52 |
| ▸ | NPY4R | P50391 | 13/20 | 0.49 |
| ▸ | NPY1R | P25929 | 9/20 | 0.49 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.49 |
| ▸ | NPY2R | P49146 | 5/20 | 0.49 |
| ▸ | MMP3 | P08254 | 4/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3868962 | 1.00 | SIRT5 (0.52) | SIRT5NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL1301360 | 0.88 | SIRT5 (0.49) | SIRT5MMP3MMP1 | |
| SCHEMBL1803249 | 0.88 | SIRT5 (0.54) | SIRT5 | |
| SCHEMBL1301358 | 0.86 | SIRT5 (0.54) | SIRT5MMP3MMP1 | |
| SCHEMBL19509389 | 0.86 | NPY4R (0.45) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL19508905 | 0.86 | NPY4R (0.45) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL8495706 | 0.85 | CTSL (0.54) | SIRT5 | |
| SCHEMBL8495526 | 0.85 | CTSL (0.54) | SIRT5 | |
| SCHEMBL1300474 | 0.84 | SIRT5 (0.46) | SIRT5NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL9490221 | 0.84 | SIRT5 (0.53) | SIRT5MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7601512-B2 | Methods for identifying inhibitors of the 20S and 26S proteasome | BAYER CROPSCIENCE AG (DE) | 2009-10-13 | — | — | US | disclosed |
| EP-1123412-B1 | METHOD FOR MONITORING PROTEASOME INHIBITOR DRUG ACTION | MILLENNIUM PHARM INC (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20040053312-A1 | Methods for identifying inhibitors of the 20S and 26S proteasome | BAYER CROPSCIENCE AG (DE) | 2004-03-18 | — | — | US | disclosed |
| US-6613541-B1 | Pharmacology; bioassay; proteolysis; enzyme inhibitors; use to provide guidance for selecting dose amount and dose frequency of proteasome inhibitors for treatment of cancer, inflammatory and autoimmune diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2003-09-02 | — | — | US | disclosed |
| US-20010051654-A1 | Treatment of inflammatory and autoimmune diseases | ELLIOTT PETER J (US) | 2001-12-13 | — | — | US | disclosed |
| EP-1123412-A1 | METHOD FOR MONITORING PROTEASOME INHIBITOR DRUG ACTION | Millennium Pharmaceuticals, Inc. (US) | 2001-08-16 | — | — | EP | disclosed |
| WO-2000023614-A1 | METHOD FOR MONITORING PROTEASOME INHIBITOR DRUG ACTION | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2000-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051654-A1 | Treatment of inflammatory and autoimmune diseases | NFKBIA, IKBKG, PSMB1 | SIRT5 2419/4885NPY4R 4353/4885NPY1R 4644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.